Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2016

Open Access 01-12-2016 | Study protocol

Design and methods of CYCLE-HD: improving cardiovascular health in patients with end stage renal disease using a structured programme of exercise: a randomised control trial

Authors: M. P. M. Graham-Brown, D. S. March, D. R. Churchward, H. M. L. Young, M. Dungey, S. Lloyd, N. J. Brunskill, A. C. Smith, G. P. McCann, J. O. Burton

Published in: BMC Nephrology | Issue 1/2016

Login to get access

Abstract

Background

There is emerging evidence that exercise training could positively impact several of the cardiovascular risk factors associated with sudden cardiac death amongst patients on haemodialysis. The primary aim of this study is to evaluate the effect of an intradialytic exercise programme on left ventricular mass.

Method and design

Prospective, randomised cluster open-label blinded endpoint clinical trial in 130 patients with end stage renal disease on haemodialysis. Patients will be randomised 1:1 to either 1) minimum of 30 min continuous cycling thrice weekly during dialysis or 2) standard care. The primary outcome is change in left ventricular mass at 6 months, assessed by cardiac MRI (CMR). In order to detect a difference in LV mass of 15 g between groups at 80 % power, a sample size of 65 patients per group is required. Secondary outcome measures include abnormalities of cardiac rhythm, left ventricular volumes and ejection fraction, physical function measures, anthropometric measures, quality of life and markers of inflammation, with interim assessment for some measures at 3 months.

Discussion

This study will test the hypothesis that an intradialytic programme of exercise leads to a regression in left ventricular mass, an important non-traditional cardiovascular risk factor in end stage renal disease. For the first time this will be assessed using CMR. We will also evaluate the efficacy, feasibility and safety of an intradialytic exercise programme using a number of secondary end-points. We anticipate that a positive outcome will lead to both an increased patient uptake into established intradialytic programmes and the development of new programmes nationally and internationally.

Trial registration number

ISRCTN11299707 (registration date 5th March 2015).
Appendix
Available only for authorised users
Literature
1.
Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16–23.PubMed
2.
U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2013.
3.
Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793–808.CrossRefPubMed
4.
U.S. Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. 2006.
5.
Herzog CA. Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome. Kidney Int. 2003;63:S197–200.CrossRef
6.
Spaulding CM, Joly L, Rosenberg A, Monchi M, Weber SN, Dhainaut JA, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med. 1997;336(23):1629–33.CrossRefPubMed
7.
Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.CrossRefPubMed
8.
Amann K, Rychlik I, Miltenberger-Milteny G, Ritz E. Left ventricular hypertrophy in renal failure. Kidney Int. 1998;54:S78–85.CrossRef
9.
Amann K, Buzello M, Simonaviciene A, Miltenberger-Miltenyi G, Koch A, Nabokov A, et al. Capillary/myocyte mismatch in the heart in renal failure--a role for erythropoietin? Nephrol Dial Transplant. 2000;15(7):964–9.CrossRefPubMed
10.
Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47(3):884–90.CrossRefPubMed
11.
Burton JO, Korsheed S, Grundy BJ, McIntyre CW. Hemodialysis-induced left ventricular dysfunction is associated with an increase in ventricular arrhythmias. Ren Fail. 2008;30(7):701–9.CrossRefPubMed
12.
Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009;4(5):914–20.CrossRefPubMedPubMedCentral
13.
Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol. 2009;4(12):1925–31.CrossRefPubMedPubMedCentral
14.
Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial. 2008;21(4):300–7.CrossRefPubMed
15.
Herzog CA, Strief JW, Collins AJ, Gilbertson DT. Cause-specific mortality of dialysis patients after coronary revascularization: why don’t dialysis patients have better survival after coronary intervention? Nephrol Dial Transplant. 2008;23(8):2629–33.CrossRefPubMedPubMedCentral
16.
Segura-Orti E. Exercise in haemodyalisis patients: a literature systematic review. Nefrologia. 2010;30(2):236–46.PubMed
17.
Sheng K, Zhang P, Chen L, Cheng J, Wu C, Chen J. Intradialytic exercise in hemodialysis patients: a systematic review and meta-analysis. Am J Nephrol. 2014;40(5):478–90.CrossRefPubMed
18.
Konstantinidou E, Koukouvou G, Kouidi E, Deligiannis A, Tourkantonis A. Exercise training in patients with end-stage renal disease on hemodialysis: comparison of three rehabilitation programs. J Rehabil Med. 2002;34(1):40–5.CrossRefPubMed
19.
Kouidi E, Grekas D, Deligiannis A, Tourkantonis A. Outcomes of long-term exercise training in dialysis patients: comparison of two training programs. Clin Nephrol. 2004;61 Suppl 1:S31–8.PubMed
20.
Hardman AE, Stensel DJ. Physical activity and health: the evidence explained. 2. Oxon: Routledge; 2009. p.38.
21.
Tentori F, Elder SJ, Thumma J, Pisoni RL, Bommer J, Fissell RB, et al. Physical exercise among participants in the Dialysis Outcomes and Practice Patterns Study (DOPPS): correlates and associated outcomes. Nephrol Dial Transplant. 2010;25(9):3050–62.CrossRefPubMed
22.
Goldberg A, Geltman E, Gavin III J, Carney R, Hagberg J, Delmez J, et al. Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. Nephron. 1986;42(4):311–6.CrossRefPubMed
23.
Vaithilingam I, Polkinghorne KR, Atkins RC, Kerr PG. Time and exercise improve phosphate removal in hemodialysis patients. Am J Kidney Dis. 2004;43(1):85–9.CrossRefPubMed
24.
Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011;11(9):607–15.CrossRefPubMed
25.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47(1):186–92.CrossRefPubMed
26.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995;5(12):2024–31.PubMed
27.
McIntyre CW, Odudu A, Eldehni MT. Cardiac assessment in chronic kidney disease. Curr Opin Nephrol Hypertens. 2009;18(6):501–6.CrossRefPubMed
28.
Stewart GA, Foster J, Cowan M, Rooney E, McDonagh T, Dargie HJ, et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int. 1999;56(6):2248–53.CrossRefPubMed
29.
Hunold P, Vogt FM, Heemann UW, Zimmermann U, Barkhausen J. Myocardial mass and volume measurement of hypertrophic left ventricles by MRI—study in dialysis patients examined before and after dialysis. J Cardiovasc Magn Reson. 2003;5(4):553–61.CrossRefPubMed
30.
Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. JACC Cardiovasc Imaging. 2014;7(7):703–14.CrossRefPubMed
31.
Rofsky NM. Nephrogenic Systemic Fibrosis: Considerations for the Cardiologist. JACC Cardiovasc Imaging. 2008;1(4):457–9.CrossRefPubMed
32.
Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99(13):932–7.CrossRefPubMedPubMedCentral
33.
Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16:99-014-0099-4.CrossRef
34.
Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev. 2015;20(2):133–44.CrossRefPubMed
35.
Tölle M, Reshetnik A, Schuchardt M, Höhne M, Giet M. Arteriosclerosis and vascular calcification: causes, clinical assessment and therapy. Eur J Clin Invest. 2015;45(9):976–85.CrossRefPubMed
36.
Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99(18):2434–9.CrossRefPubMed
37.
Wang M, Tsai W, Chen J, Huang J. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis. 2005;45(3):494–501.CrossRefPubMed
38.
Briet M, Bozec E, Laurent S, Fassot C, London G, Jacquot C, et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int. 2006;69(2):350–7.CrossRefPubMed
39.
40.
Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. Heart. 2013;99(6):365–72.CrossRefPubMed
41.
Chue CD, Edwards NC, Ferro CJ, Townend JN, Steeds RP. Effects of age and chronic kidney disease on regional aortic distensibility: a cardiovascular magnetic resonance study. Int J Cardiol. 2013;168(4):4249–54.CrossRefPubMed
42.
Ibrahim EH. Myocardial tagging by cardiovascular magnetic resonance: evolution of techniques–pulse sequences, analysis algorithms, and applications. J Cardiovasc Magn Reson. 2011;13(1):36.CrossRefPubMedCentral
43.
Edwards NC, Noori A, Chue CD, Moody WE, Ferro CJ, Townend JN, et al. Impaired circumferential and longitudinal myocardial deformation in early stage chronic kidney disease: the earliest features of uremic cardiomyopathy. J Cardiovasc Magn Reson. 2013;15(1):1–2.CrossRef
44.
Khan JN, Singh A, Nazir SA, Kanagala P, Gershlick AH, McCann GP. Comparison of cardiovascular magnetic resonance feature tracking and tagging for the assessment of left ventricular systolic strain in acute myocardial infarction. Eur J Radiol. 2015;84(5):840–8.CrossRefPubMed
45.
Singh A, Steadman CD, Khan JN, Horsfield MA, Bekele S, Nazir SA, et al. Intertechnique agreement and interstudy reproducibility of strain and diastolic strain rate at 1.5 and 3 tesla: A comparison of feature‐tracking and tagging in patients with aortic stenosis. J Magn Reson Imaging. 2015;41(4):1129–37.CrossRefPubMed
46.
Singh A, Ford I, Greenwood JP, Khan JN, Uddin A, Berry C, et al. Rationale and design of the PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations. BMJ Open. 2013;3(12):e004348-2013-004348.CrossRef
47.
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39. e14.CrossRefPubMed
48.
London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759–67.PubMed
49.
Mahmod M, Piechnik SK, Levelt E, Ferreira VM, Francis JM, Lewis A, et al. Adenosine stress native T1 mapping in severe aortic stenosis: evidence for a role of the intravascular compartment on myocardial T1 values. J Cardiovasc Magn Reson. 2014;16:92-014-0092-y.
50.
Dandekar VK, Bauml MA, Ertel AW, Dickens C, Gonzalez RC, Farzaneh-Far A. Assessment of global myocardial perfusion reserve using cardiovascular magnetic resonance of coronary sinus flow at 3 Tesla. J Cardiovasc Magn Reson. 2014;16(1):24.CrossRefPubMedPubMedCentral
51.
Losi MA, Memoli B, Contaldi C, Barbati G, Del Prete M, Betocchi S, et al. Myocardial fibrosis and diastolic dysfunction in patients on chronic haemodialysis. Nephrol Dial Transplant. 2010;25(6):1950–4.CrossRefPubMed
52.
Salvetti M, Muiesan ML, Paini A, Monteduro C, Bonzi B, Galbassini G, et al. Myocardial ultrasound tissue characterization in patients with chronic renal failure. J Am Soc Nephrol. 2007;18(6):1953–8.CrossRefPubMed
53.
Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L, et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation. 1990;81(1):58–64.CrossRefPubMed
54.
Fujimoto S, Mizuno R, Nakagawa Y, Kimura A, Yamaji K, Yutani C, et al. Ultrasonic tissue characterization in patients with dilated cardiomyopathy: comparison with findings from right ventricular endomyocardial biopsy. Int J Card Imaging. 1999;15(5):391–6.CrossRefPubMed
55.
Lythall D, Bishop J, Greenbaum R, Ilsley C, Mitchell A, Gibson D, et al. Relationship between myocardial collagen and echo amplitude in non-fibrotic hearts. Eur Heart J. 1993;14(3):344–50.CrossRefPubMed
56.
Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol. 2009;53(18):1621–8.CrossRefPubMed
57.
Raval NY, Squara P, Cleman M, Yalamanchili K, Winklmaier M, Burkhoff D. Multicenter evaluation of noninvasive cardiac output measurement by bioreactance technique. J Clin Monit Comput. 2008;22(2):113–9.CrossRefPubMed
58.
Keren H, Burkhoff D, Squara P. Evaluation of a noninvasive continuous cardiac output monitoring system based on thoracic bioreactance. Am J Physiol Heart Circ Physiol. 2007;293(1):H583–9.CrossRefPubMed
59.
Kossari N, Hufnagel G, Squara P. Bioreactance: a new tool for cardiac output and thoracic fluid content monitoring during hemodialysis. Hemodial Int. 2009;13(4):512–7.CrossRefPubMed
60.
McIntyre CW, Selby NM, Sigrist M, Pearce LE, Mercer TH, Naish PF. Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. Nephrol Dial Transplant. 2006;21(8):2210–6.CrossRefPubMed
61.
Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55(4):M221–31.CrossRefPubMed
62.
Cheema B, Abas H, Smith B, O’Sullivan A, Chan M, Patwardhan A, et al. Progressive exercise for anabolism in kidney disease (PEAK): a randomized, controlled trial of resistance training during hemodialysis. J Am Soc Nephrol. 2007;18(5):1594–601.CrossRefPubMed
63.
Wabel P, Rode C, Moissl U, Chamney P, Wizemann V. Accuracy of bioimpedance spectroscopy (BIS) to detect fluid status changes in hemodialysis patients. Nephrol Dial Transplant. 2007;22 Suppl 6:VI129.
64.
Chamney PW, Wabel P, Moissl UM, Muller MJ, Bosy-Westphal A, Korth O, et al. A whole-body model to distinguish excess fluid from the hydration of major body tissues. Am J Clin Nutr. 2007;85(1):80–9.PubMed
65.
Chamney PW, Krämer M, Rode C, Kleinekofort W, Wizemann V. A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance. Kidney Int. 2002;61(6):2250–8.CrossRefPubMed
66.
Hundley WG, Bluemke D, Bogaert JG, Friedrich MG, Higgins CB, Lawson MA, et al. Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson. 2009;11:5-429X-11-5.CrossRef
67.
Maroules CD, Khera A, Ayers C, Goel A, Peshock RM, Abbara S, et al. Cardiovascular outcome associations among cardiovascular magnetic resonance measures of arterial stiffness: the Dallas heart study. J Cardiovasc Magn Reson. 2014;16:33-429X-16-33.CrossRef
68.
Bramwell JC, Hill A. Velocity of transmission of the pulse-wave: and elasticity of arteries. Lancet. 1922;199(5149):891–2.CrossRef
69.
Mactier R, Hoenich N, Breen C. UK Renal Association Clinical Practice Guidelines: Haemodialysis. 2009.
70.
Borg GA. Perceived exertion: a note on “history” and methods. Med Sci Sports. 1973;5(2):90–3.PubMed
71.
Clarke A, Young H, Dungey M, Hudson N, Westacott R, Burton J, Smith A. Patient and staff perspectives after implementation of an intradialytic cycling programme: A qualitative study, British Renal Society Annual Conference. 2013.
72.
Kouidi EJ, Grekas DM, Deligiannis AP. Effects of exercise training on noninvasive cardiac measures in patients undergoing long-term hemodialysis: a randomized controlled trial. Am J Kidney Dis. 2009;54(3):511–21.CrossRefPubMed
73.
Turner MJ, Spina RJ, Kohrt WM, Ehsani AA. Effect of endurance exercise training on left ventricular size and remodeling in older adults with hypertension. J Gerontol A Biol Sci Med Sci. 2000;55(4):M245–51.CrossRefPubMed
74.
Trial Group FHN, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287–300.CrossRef
75.
Young H, Dungey M, Watson EL, Baines RJ, Burton JO, Smith AC. Exercise in end stage renal failure: patient perceived barriers and motivators, British Renal Society Annual Conference. 2012. p. 18.
76.
Khan JN, Razvi N, Nazir SA, Singh A, Masca NG, Gershlick AH, et al. Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction. J Cardiovasc Magn Reson. 2014;16:38.CrossRefPubMedPubMedCentral
77.
Steadman CD, Jerosch-Herold M, Grundy B, Rafelt S, Ng LL, Squire IB, et al. Determinants and functional significance of myocardial perfusion reserve in severe aortic stenosis. JACC Cardiovasc Imaging. 2012;5(2):182–9.CrossRefPubMed
78.
Delgado C, Johansen KL. Barriers to exercise participation among dialysis patients. Nephrol Dial Transplant. 2012;27(3):1152–7.CrossRefPubMed
79.
Goodman ED, Ballou MB. Perceived barriers and motivators to exercise in hemodialysis patients. Nephrol Nurs J. 2004;31(1):23–9.PubMed
80.
81.
Painter P, Clark L, Olausson J. Physical function and physical activity assessment and promotion in the hemodialysis clinic: a qualitative study. Am J Kidney Dis. 2014;64(3):425–33.CrossRefPubMed
82.
Ma S, Lui J, Brooks D, Parsons TL. The availability of exercise rehabilitation programs in hemodialysis centres in Ontario. CANNT J. 2012;22(4):26–32.PubMed
83.
Metadata
Title
Design and methods of CYCLE-HD: improving cardiovascular health in patients with end stage renal disease using a structured programme of exercise: a randomised control trial
Authors
M. P. M. Graham-Brown
D. S. March
D. R. Churchward
H. M. L. Young
M. Dungey
S. Lloyd
N. J. Brunskill
A. C. Smith
G. P. McCann
J. O. Burton
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2016
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-016-0294-7

Other articles of this Issue 1/2016

BMC Nephrology 1/2016 Go to the issue

Research article

HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study

Research article

High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study

Study protocol

Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease

Research article

Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Research article

Efficacy of the Essential Amino Acids and Keto-Analogues on the CKD progression rate in real practice in Russia - city nephrology registry data for outpatient clinic

Research article

Health related quality of life in patients with end stage kidney disease treated with haemodialysis in Malawi: a cross sectional study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits